The authors of a small Italian study of hospitalized COVID-19 patients speculated that reversible transient factors, such as inflammation-induced insulin resistance, may cause the hyperglycemia that occurs in some patients with and without diabetes
The results of a retrospective study of U.S. data in patients with both diabetes and end-stage kidney disease (ESKD) indicate that current glycemic monitoring and treatment in this population are suboptimal, the authors said.
Patients with type 2 diabetes and a systolic blood pressure of 110 to 119 mm Hg appeared to have a lower risk of cardiovascular disease than patients who had systolic blood pressures of 130 to 139 mm Hg, according to a registry study.
The study looked at data from the Sweden National Diabetes Register to determine what patient characteristics were related to all-cause mortality or death from cardiovascular-, diabetes-, or cancer-related causes.
The U.K.-based retrospective cohort study used a database that linked national hospitalization and mortality data for people who were prescribed second-line regimens after metformin.
Intensive treatment was defined as use of more glucose-lowering medications than recommended by practice guidelines and was found in 18.7% of clinically complex Medicare patients.
Excess mortality associated with diabetes was highest in patients younger than age 75 who had had diabetes for a longer time period, with the relative hazard highest in women, a study found.
A 1-hour glucose value above 155 mg/dL predicted mortality even when the 2-hour glucose value was below 140 mg/dL, according to the 33-year study.
The results of this study pose the question of whether the increased likelihood of bladder cancer, which is rare, justifies withholding pioglitazone from adults with type 2 diabetes, according to an accompanying editorial.
Researchers compared patients taking dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues to those taking 2 or more oral antidiabetic drugs.